• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Renal Cancer Resistance to VEGF Receptor Tyrosine Kinase Inhibitors. 
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • Renal Cancer Resistance to VEGF Receptor Tyrosine Kinase Inhibitors.
    •   QMRO Home
    • Queen Mary University of London Theses
    • Theses
    • Renal Cancer Resistance to VEGF Receptor Tyrosine Kinase Inhibitors.
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Renal Cancer Resistance to VEGF Receptor Tyrosine Kinase Inhibitors.

    View/Open
    Sharpe_Kevin_PhD_Final_301015.pdf (3.902Mb)
    Publisher
    Queen Mary University of London
    Metadata
    Show full item record
    Abstract
    Aim: To investigates the molecular changes that occur in response to VEGFr TKI therapy to better understand the acquired resistance process. A further goal is to investigate the potential of SRC inhibitors to slow or prevent VEGFr TKI resistance. Methods: Work was conducted in in vitro assays (MTS assays, scratch and transwell migration assays), a preclinical in vivo model of resistance (786-O xenografts) and IHC was conducted in sequential RCC patient tissue taken before and after 12-16 weeks of VEGFr TKI therapy. Findings: 100% (n=15) of 786-O xenografts developed a resistant phenotype when continually exposed to VEGFr-TKI treatment. PCR with species-specific probes showed VEGFr-TKI induced significant up-regulation of several pro-angiogenic factors in both the tumour and host compartments. These factors included VEGF ligand, FGF-2, HGF, and MET receptor. In addition, genes associated with epithelial mesenchymal transition were up-regulated in treated xenografts. Interestingly, the pro-angiogenic factor PGF and the pro-metastatic gene s100a4 were up-regulated with time, independently of treatment. Gene pathway analysis suggested VEGFr-TKI treatment induced a process resembling fibrosis or wound healing. Furthermore, collagen was increased in treated xenografts. IHC in RCC patient tissue verified that some of the above pathways were affected in the clinical setting. VEGFr-TKI treatment caused a significant reduction in vessel density (CD31), and up-regulation of FGF-2 ligand and vessel-bound MET receptor. Collagen was also increased in VEGFr-TKI treated clinical samples. In vitro assays demonstrated that VHL gene mutation promoted resistance to SRC TKIs. Adding a SRC TKI to VEGFr-TKI therapy had a synergistic anti-tumour effect on 786-O xenografts. However, the combination could not prevent growth in tumours that had acquired a VEGFr TKI resistant phenotype. There was no evidence that the addition of a SRC TKI affected genes implicated in the resistance process. Interpretation: VEGFr-TKI treatment is associated with dynamic molecular changes to several relevant biomarkers. Targeting any one pathway in isolation may have an incremental anti-tumour effect, but because multiple pathways are affected, it is perhaps unlikely to result in a sustained improvement in tumour response. Heterogeneity of protein expression adds further complication to a targeted approach. Collagen deposition increases with VEGFr TKI therapy. Collagen has been shown to promote angiogenesis and metastasis. Further investigation is warranted to understand whether the addition of anti-fibrotic agents to anti-angiogenic therapy could have an incremental benefit on patient outcome.
    Authors
    Sharpe, Kevin
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/12924
    Collections
    • Theses [3711]
    Copyright statements
    The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.